Corinne Beinat1, Chirag B Patel1,2, Yuanyang Xie1,3, Sanjiv S Gambhir4,5. 1. Molecular Imaging Program at Stanford, Department of Radiology, James H. Clark Center, Stanford University School of Medicine, 318 Campus Drive, E153, Stanford, CA, 94305, USA. 2. Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA. 3. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410002, Hunan, China. 4. Molecular Imaging Program at Stanford, Department of Radiology, James H. Clark Center, Stanford University School of Medicine, 318 Campus Drive, E153, Stanford, CA, 94305, USA. sgambhir@stanford.edu. 5. Department of Bioengineering and Materials Science and Engineering, Bio-X, Stanford University, Stanford, CA, 94305, USA. sgambhir@stanford.edu.
Abstract
PURPOSE: Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, the key process of tumor metabolism. PKM2 is found in high levels in glioblastoma (GBM) cells with marginal expression within healthy brain tissue, rendering it a key biomarker of GBM metabolic re-programming. Our group has reported the development of a novel radiotracer, 1-((2-fluoro- 6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([18F]DASA- 23), to non-invasively detect PKM2 levels with positron emission tomography (PET). PROCEDURE: U87 human GBM cells were treated with the IC50 concentration of various agents used in the treatment of GBM, including alkylating agents (temozolomide, carmustine, lomustine, procarbazine), inhibitor of topoisomerase I (irinotecan), vascular endothelial and epidermal growth factor receptor inhibitors (cediranib and erlotinib, respectively) anti-metabolite (5-fluorouracil), microtubule inhibitor (vincristine), and metabolic agents (dichloroacetate and IDH1 inhibitor ivosidenib). Following drug exposure for three or 6 days (n = 6 replicates per condition), the radiotracer uptake of [18F]DASA-23 and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) was assessed. Changes in PKM2 protein levels were determined via Western blot and correlated to radiotracer uptake. RESULTS: Significant interactions were found between the treatment agent (n = 12 conditions total comprised 11 drugs and vehicle) and the duration of treatment (3- or 6-day exposure to each drug) on the cellular uptake of [18F]DASA-23 (p = 0.0001). The greatest change in the cellular uptake of [18F]DASA-23 was found after exposure to alkylating agents (p < 0. 0001) followed by irinotecan (p = 0. 0012), erlotinib (p = 0. 02), and 5-fluorouracil (p = 0. 005). Correlation of PKM2 protein levels and [18F]DASA-23 cellular uptake revealed a moderate correlation (r = 0.44, p = 0.15). CONCLUSIONS: These proof of principle studies emphasize the superiority of [18F]DASA-23 to [18F]FDG in detecting the glycolytic response of GBM to multiple classes of anti-neoplastic drugs in cell culture. A clinical trial evaluating the diagnostic utility of [18F]DASA-23 PET in GBM patients (NCT03539731) is ongoing.
PURPOSE:Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, the key process of tumor metabolism. PKM2 is found in high levels in glioblastoma (GBM) cells with marginal expression within healthy brain tissue, rendering it a key biomarker of GBM metabolic re-programming. Our group has reported the development of a novel radiotracer, 1-((2-fluoro- 6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([18F]DASA- 23), to non-invasively detect PKM2 levels with positron emission tomography (PET). PROCEDURE: U87human GBM cells were treated with the IC50 concentration of various agents used in the treatment of GBM, including alkylating agents (temozolomide, carmustine, lomustine, procarbazine), inhibitor of topoisomerase I (irinotecan), vascular endothelial and epidermal growth factor receptor inhibitors (cediranib and erlotinib, respectively) anti-metabolite (5-fluorouracil), microtubule inhibitor (vincristine), and metabolic agents (dichloroacetate and IDH1 inhibitor ivosidenib). Following drug exposure for three or 6 days (n = 6 replicates per condition), the radiotracer uptake of [18F]DASA-23 and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) was assessed. Changes in PKM2 protein levels were determined via Western blot and correlated to radiotracer uptake. RESULTS: Significant interactions were found between the treatment agent (n = 12 conditions total comprised 11 drugs and vehicle) and the duration of treatment (3- or 6-day exposure to each drug) on the cellular uptake of [18F]DASA-23 (p = 0.0001). The greatest change in the cellular uptake of [18F]DASA-23 was found after exposure to alkylating agents (p < 0. 0001) followed by irinotecan (p = 0. 0012), erlotinib (p = 0. 02), and 5-fluorouracil (p = 0. 005). Correlation of PKM2 protein levels and [18F]DASA-23 cellular uptake revealed a moderate correlation (r = 0.44, p = 0.15). CONCLUSIONS: These proof of principle studies emphasize the superiority of [18F]DASA-23 to [18F]FDG in detecting the glycolytic response of GBM to multiple classes of anti-neoplastic drugs in cell culture. A clinical trial evaluating the diagnostic utility of [18F]DASA-23 PET in GBM patients (NCT03539731) is ongoing.
Authors: L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen Journal: AJNR Am J Neuroradiol Date: 2011-03-10 Impact factor: 3.825
Authors: Dimitrios Anastasiou; George Poulogiannis; John M Asara; Matthew B Boxer; Jian-kang Jiang; Min Shen; Gary Bellinger; Atsuo T Sasaki; Jason W Locasale; Douglas S Auld; Craig J Thomas; Matthew G Vander Heiden; Lewis C Cantley Journal: Science Date: 2011-11-03 Impact factor: 47.728
Authors: Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: Ilwoo Park; Joydeep Mukherjee; Motokazu Ito; Myriam M Chaumeil; Llewellyn E Jalbert; Karin Gaensler; Sabrina M Ronen; Sarah J Nelson; Russell O Pieper Journal: Cancer Res Date: 2014-10-15 Impact factor: 12.701
Authors: Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley Journal: Nature Date: 2008-03-13 Impact factor: 49.962
Authors: J Pruim; A T Willemsen; W M Molenaar; A van Waarde; A M Paans; M A Heesters; K G Go; G M Visser; E J Franssen; W Vaalburg Journal: Radiology Date: 1995-10 Impact factor: 11.105
Authors: Corinne Beinat; Chirag B Patel; Tom Haywood; Surya Murty; Lewis Naya; Jessa B Castillo; Samantha T Reyes; Megan Phillips; Pablo Buccino; Bin Shen; Jun Hyung Park; Mary Ellen I Koran; Israt S Alam; Michelle L James; Dawn Holley; Kim Halbert; Harsh Gandhi; Joy Q He; Monica Granucci; Eli Johnson; Daniel Dan Liu; Nobuko Uchida; Rahul Sinha; Pauline Chu; Donald E Born; Geoffrey I Warnock; Irving Weissman; Melanie Hayden-Gephart; Mehdi Khalighi; Tarik F Massoud; Andrei Iagaru; Guido Davidzon; Reena Thomas; Seema Nagpal; Lawrence D Recht; Sanjiv Sam Gambhir Journal: Clin Cancer Res Date: 2021-09-02 Impact factor: 13.801
Authors: Pinar Uysal-Onganer; Amy MacLatchy; Rayan Mahmoud; Igor Kraev; Paul R Thompson; Jameel M Inal; Sigrun Lange Journal: Int J Mol Sci Date: 2020-02-22 Impact factor: 5.923